ArticleACS catalysis2025
Article in ACS catalysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cationic diruthenium (II,III) tetracarboxylate catalysts have been shown to catalyze selective intermolecular C-H functionalization reactions using donor/acceptor carbenes in high yield and with high levels of enantioselectivity. The diruthenium catalysts were compared to the analogous dirhodium (II,II) tetracarboxylate and showed similar levels of enantioselectivity for most reactions. A distinctive feature of the diruthenium catalysts is a greater preference for C-H functionalization over cyclopropanation compared to the corresponding dirhodium catalysts. Also, the diruthenium catalysts have a greater preference for sterically more accessible sites compared with their dirhodium counterparts. These studies show that the diruthenium catalysts are generally effective catalysts for enantioselective intermolecular C-H functionalization, but further optimization would be needed for them to match the dirhodium catalysts in terms of functional group compatibility, turnover frequency, and turnover numbers.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.